Open-Label, Dose-Escalating, Clinical and Pharmacokinetic Phase I Study of Lurbinectedin (PM01183) in Patients With Advanced Acute Leukemia or Relapsed/Refractory Myelodysplastic Syndrome

Trial Profile

Open-Label, Dose-Escalating, Clinical and Pharmacokinetic Phase I Study of Lurbinectedin (PM01183) in Patients With Advanced Acute Leukemia or Relapsed/Refractory Myelodysplastic Syndrome

Completed
Phase of Trial: Phase I

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs Lurbinectedin (Primary)
  • Indications Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Chronic myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
  • Focus Adverse reactions
  • Sponsors PharmaMar
  • Most Recent Events

    • 06 Jun 2017 Results (n=42) assessing the safety, tolerability, and pharmacogenetics presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
    • 27 Jul 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 09 Feb 2015 Planned End Date changed from 1 Sep 2015 to 1 Jan 2016 as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top